Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

bmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to raise and maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2011201020112010Revenues:Collaborative agreement $

857$

286$

2,571$

286License revenue 02297166Total revenues 8573083,542352Operating expenses:Research and development 1,5398,18611,23721,753General and administrative 3,9076,62415,87018,827Total operating expenses 5,44614,81027,10740,580Loss from operations (4,589)(14,502)(23,565)(40,228)Other income (expense):Interest income 92135101Interest expense -(165)(221)(501)Total other income (expense) 9(144)(186)(400)Net loss $

(4,580)$

(14,646)$

(23,751)$

(40,628)Net loss per share - basic and diluted $

(0.10)$

(0.31)$

(0.
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... , May 1, 2015 ... market for antithrombotic drugs will reach $22.4bn in 2019. ... Drugs: World Industry and Market Prospects 2015-2025 ... of that investigation is to provide forecasts and qualitative ... business information publisher and consultancy in London, ...
(Date:5/1/2015)... Albany Molecular Research Inc. (NASDAQ: AMRI ... AMRI,s President and Chief Executive Officer, will present at ... Conference on Wednesday, May 13, 2015 at 4:20 p.m. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
(Date:5/1/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... Care Conference in Boston, Massachusetts . ... 2015, at 3:30 PM Eastern Time, and can be accessed ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... presentation Sunday, May 17, 8:15 a.m. PDT - - ... p.m. PDT - - Conference call and webcast Tuesday, ... 14 InterMune, Inc. (Nasdaq: ITMN ) today ... presentations related to the company,s pulmonology programs will be presented ...
... substantially increased capacity, for continued growth,TORONTO, ... today robust double digit growth in sales, improved cash ... ended March 31, 2009. , In a news release ... 43% growth in the first half of 2009 coupled ...
... Dendreon Corporation today announced that Chief Executive Officer, ... Ernst & Young Entrepreneur Of The Year (R) ... Ernst & Young LLP, the awards program recognizes entrepreneurs ... financial performance and personal commitment to their businesses and ...
Cached Biology Technology:Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... TALLAHASSEE, Fla. -- Reductions in the flow of the ... to grouper and other reef fish populations in the ... State University study that may provide new ammunition for ... The Florida State researchers found that in years with ...
... The SIB Swiss Institute of Bioinformatics today announced the winners ... Young Bioinformatician Award at the 7th annual [BC]2 Basel Computational ... , The winner of the 2009 SIB Young Bioinformatician ... working for the past four years with the SIB in ...
... Discovered Interferon Response May Offer Early Control of H5N1 Influenza ... protein, interferon type 1, reduced H5N1 influenza virus replication in ... early stages of infection. They report their findings in ... . Highly pathogenic avian influenza H5N1 ...
Cached Biology News:Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 2Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 3The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4
... the DH-2000, but comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium ... of deuterium and tungsten halogen light sources in ... produces a powerful, stable output from 215-200 nm. ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... Nematode microRNA Microarray contains all known ...
... critical to the maintenance of appropriate ... as important and diverse as those ... and stress response, antigen presentation, modulation ... channels, cell cycle regulation, transcription, and ...
Biology Products: